Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.
Location: United States, Pennsylvania, Philadelphia
Employees: 51-200
Total raised: $410M
Founded date: 2018
Investors 3
| Date | Name | Website |
| 17.08.2021 | Logos Capi... | logoscapit... |
| - | Octagon Ca... | octagoninv... |
| - | RA Capital... | racap.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.03.2021 | Series C | $160M | - |
| 01.07.2019 | - | $250M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Daniel | Geffken | Senior Fin... | linkedin.c... | - | - |
Mentions in press and media 8
| Date | Title | Description |
| 05.03.2024 | Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting | - |
| 11.01.2022 | Money Moves: Century Therapeutics made a $150M deal with Bristol Myers Squibb | Money Moves is a column where we chart the funding raises of tech companies across the region. Have a tip? Email us at philly@technical.ly. University City-based cell therapy company Century Therapeutics has entered into a $150 million part... |
| 12.08.2021 | Century Therapeutics : Reports Second Quarter 2021 Financial Results and Business Updates (Form 8-K) | Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates Continued Company investment across our iPSC platforms, programs and manufacturing Lead program, CNTY-101, remains on track for IND filing in mid-2022 R... |
| 12.08.2021 | Century Therapeutics : Reports Second Quarter 2021 Financial Results and Business Updates | Continued Company investment across our iPSC platforms, programs, and manufacturing Lead program, CNTY-101, remains on track for IND filing in mid-2022 Recent IPO with net proceeds of approximately $221M June 30, 2021 cash, cash equivalents... |
| 05.05.2021 | Century Therapeutics Expands Board of Directors with Key Appointments | |
| 04.03.2021 | Century Therapeutics Closes $160M Series C Financing | Century Therapeutics, a Philadelphia, PA-based cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, closed a $160m Series C financing. The round was led by Casdin Capital and brough... |
| 03.03.2021 | Century Therapeutics Completes $160 Million Series C Financing to Accelerate Development of iPSC-derived Cell Therapy Pipeline | |
| 17.02.2021 | Century Therapeutics Significantly Expands Capabilities with New Operational, Laboratory and Manufacturing Facilities in Pennsylvania and New Jersey |